Y. Yan

941 total citations
24 papers, 718 citations indexed

About

Y. Yan is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Y. Yan has authored 24 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Y. Yan's work include Melanoma and MAPK Pathways (8 papers), CAR-T cell therapy research (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Y. Yan is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), CAR-T cell therapy research (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Y. Yan collaborates with scholars based in United States, United Kingdom and Australia. Y. Yan's co-authors include Alexander D. Borowsky, Mary Lynn Duckworth, Robert J. Matusik, Norman M. Pettigrew, Patricia Sheppard, Siegfried Kasper, Janice G. Dodd, Gail S. Prins, B W Erickson and Neil B. Tweedy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Y. Yan

23 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y. Yan United States	12	415	267	193	90	82	24	718
Emmy D.G. Fleuren Netherlands	17	497 1.2×	368 1.4×	307 1.6×	76 0.8×	108 1.3×	25	871
Johann Kern Germany	18	454 1.1×	208 0.8×	98 0.5×	73 0.8×	162 2.0×	55	863
Hitomi Sudo Japan	17	246 0.6×	235 0.9×	167 0.9×	61 0.7×	100 1.2×	56	766
Nadège Gaborit France	18	370 0.9×	449 1.7×	156 0.8×	68 0.8×	65 0.8×	24	773
Gregory Cesarone United States	9	304 0.7×	260 1.0×	142 0.7×	22 0.2×	65 0.8×	13	653
Minna Niemelä Finland	3	474 1.1×	242 0.9×	70 0.4×	51 0.6×	88 1.1×	3	702
Hayriye V. Erkizan United States	15	657 1.6×	236 0.9×	415 2.2×	55 0.6×	114 1.4×	20	981
Edina Komlódi-Pásztor United States	9	439 1.1×	319 1.2×	58 0.3×	76 0.8×	78 1.0×	17	793
Julie S. Barber-Rotenberg United States	8	350 0.8×	204 0.8×	243 1.3×	65 0.7×	43 0.5×	11	608
Chelsea Mayoh Australia	19	549 1.3×	267 1.0×	248 1.3×	105 1.2×	286 3.5×	59	1.1k

Countries citing papers authored by Y. Yan

Since Specialization

Citations

This map shows the geographic impact of Y. Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Yan more than expected).

Fields of papers citing papers by Y. Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Yan. The network helps show where Y. Yan may publish in the future.

Co-authorship network of co-authors of Y. Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Yan. A scholar is included among the top collaborators of Y. Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Yan. Y. Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Y., et al.. (2025). Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data. Journal of Alzheimer s Disease. 103(3). 844–855. 2 indexed citations

Sui, Yang, Hao Zhang, Y. Yan, et al.. (2025). Inhibition of DJ-1 induces TFAM secretion from cancer cells to suppress tumor growth via promoting M1 macrophage polarization. Cellular Signalling. 131. 111765–111765. 1 indexed citations

Shen, Yanping, Yun Chen, Lingli Li, Y. Yan, & Yanan Xu. (2024). Circ_0008927 Promotes the Progression of Endometriosis via miR-608-/PROM2-Mediated Ferroptosis. Gynecologic and Obstetric Investigation. 90(4). 305–318. 1 indexed citations

Sherman, Eric J., Philip R. Debruyne, Bhumsuk Keam, et al.. (2023). Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. ESMO Open. 8(2). 100877–100877. 11 indexed citations

Song, Ningning, Bo Li, Dandan Li, & Y. Yan. (2023). Hyaluronic acid-modified metal–organic framework for two-photon imaging-guided photodynamic therapy in triple negative breast cancer. APL Materials. 11(8). 4 indexed citations

Robert, Caroline, Karl D. Lewis, Ralf Gutzmer, et al.. (2022). Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma. Annals of Oncology. 33(5). 544–555. 20 indexed citations

Brufsky, Adam, S.B. Kim, Zanete Zvirbule, et al.. (2021). A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology. 32(5). 652–660. 67 indexed citations

Trinh, Huong, et al.. (2020). 446P Real-world data (RWD) survival analysis of first line (1L) metastatic colorectal cancer (mCRC) patients (pts) with BRAF V600 and non-V600, KRAS G12 and G13, and NRAS mutations. Annals of Oncology. 31. S431–S431.

Gogas, Helen, Brigitte Dréno, James Larkin, et al.. (2020). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of Oncology. 32(3). 384–394. 71 indexed citations

10.

Ascierto, Paolo A., Karl D. Lewis, Anna Maria Di Giacomo, et al.. (2020). Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib. Annals of Oncology. 31(1). 153–159. 29 indexed citations

11.

Yan, Y., Caroline Robert, James Larkin, et al.. (2016). Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Annals of Oncology. 27. vi379–vi379. 7 indexed citations

12.

McArthur, Grant A., James Larkin, Brigitte Dréno, et al.. (2015). 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. European Journal of Cancer. 51. S722–S723. 7 indexed citations

13.

Yan, Y., Grant A. McArthur, Thomas F. Gajewski, et al.. (2014). Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600 Mutation–Positive Locally Advanced or Metastatic Melanoma from Brim7 Study. Annals of Oncology. 25. iv378–iv378. 2 indexed citations

14.

Munugalavadla, Veerendra, Sanjeev Mariathasan, Dionysos Slaga, et al.. (2013). The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 33(3). 316–325. 37 indexed citations

15.

Tabernero, Josep, Cristina Saura, Susana Roselló, et al.. (2011). First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.. Journal of Clinical Oncology. 29(15_suppl). 3022–3022. 10 indexed citations

16.

Wagner, Andrew J., Patricia LoRusso, Raoul Tibes, et al.. (2009). A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3501–3501. 53 indexed citations

17.

DenBesten, Pamela K., et al.. (2002). Effects of fluoride on rat dental enamel matrix proteinases. Archives of Oral Biology. 47(11). 763–770. 60 indexed citations

18.

Kasper, Siegfried, Patricia Sheppard, Y. Yan, et al.. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.. PubMed. 78(3). 319–33. 174 indexed citations

19.

Yan, Y., Alexander Tropsha, J. J. Hérmans, & B W Erickson. (1993). Free energies for refolding of the common beta turn into the inverse-common beta turn: simulation of the role of D/L chirality.. Proceedings of the National Academy of Sciences. 90(16). 7898–7902. 24 indexed citations

20.

Richardson, Jane S., David Richardson, Neil B. Tweedy, et al.. (1992). Looking at proteins: representations, folding, packing, and design. Biophysical Society National Lecture, 1992.. PubMed. 63(5). 1185–209. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact